Why Cancer Treatments Are About To Get Smarter!

How do we remove the guesswork in cancer? So we're going to talk about N of 1 precision oncology and how this transforms the entire cancer landscape. Taking the guesswork out of cancer is so important. For decades, cancer has just been guided by averages. Double blind clinical trials, average outcomes. For some patients, it works, others it doesn't. Average tumor information, you know, only maybe a couple of dozen data points. Biopsy, tumor markers, imaging, average results. Treatment isn't working the way we want it to long term. But cancer isn't about averages. Every tumor is unique and has its own fingerprint. And that's why the future is based on N of 1 Precision Oncology treatment that is designed just for you. It is so critical. For the last 25 years, my team and I have been working on this area of n of 1 precision oncology, and we have seen the major difference that has made for patients. And in our medical center at invita, we've helped thousands of patients to get targeted care when they failed hospitals across the country with this technology. In our published 2024 paper, we showed 34 times better treatment responses than standard care oncology for late ST cancers that only had a 2% response rate and 43 times better quality of life. This is the number one thing, right? Because quality of life is key, because of precision oncology and 95 times fewer side effects. And that's just not incremental progress. That's an entirely different category of oncology. We like to call Medicine 3.0. In the oncology space. The problem with the old model of traditional double blind clinical trials is where it's built. For an era where we didn't know much about cancer biology, we didn't understand its heterogeneicity, its uniqueness, all of its biomarkers and targets. Patients with the same type and stage of cancer, you give them all the same thing. Some half of them get the drug, half get a placebo, and then we measure the difference in the outcome. But here's the problem. That approach ignores thousands of molecular targets, differences between tumors, between patients, and more importantly, it doesn't hit the targets that they need in the way that precision can. And for patients with advanced cancers, it often means they get the wrong treatment or they get a lot of side effects and they never get the care designed uniquely for their cancer in the first place. The first evidence we saw of precision on oncologies were studies like I predict and wither, where they published in nature medicine improve that. The more genetic matching you had or target matching, you had a better Outcome and you got targeted drugs and the better the patients responded and those with high matching scores lived longer, meaning the more targets they got treated, the better. And that controlled the disease and gave a better quality of life and outcome. In the wither trials they went a step further. They showed that matching the transcriptomics, the RNA activity map on your own tumor with genomics, they had more effective care overall. This multi omics approach reaches patients who would have been completely missed by traditional cancer testing alone. That's just standard genomics. Both sides point to the same truth. When you match treatment to all of the patient's actual targets, you get better results. Now, how precision oncology works, at least in my experience with Envita over the last 25 years, is it's at an entirely different level. It's RNA, so that's Transcriptomics, it's DNA genomics, it's immune profiling and spatial biology and metabolomics. And then all of this goes to work along with the standard imaging, biopsy and tumor markers. And we gather thousands, thousands of data points and those are custom matched off label and integrative agents to hit those targets. And that's the huge advantage is the custom drug design to fit with the patient needs. Transcriptomics genes are active in driving growth like rna. Immune profiling, how the immune system is responding. Is it hot or cold? Is it going throughout the body and actually finding the cancer? Is it evading it? Spatial biology helps us to map things like tumor microenvironment and understand how the immune system is being blocked or what needs to be done for the cancer to overcome its resistance. Root cause analysis helps us to look at infections. Chemical toxins, heavy metals, give you an example. We knew years ago that infections like Lyme disease were linked to breast cancer. And just a few years ago study was published to that proved that. But we saw that. So whenever people have infections, whether they're tick borne, viral, bacterial, mycotoxin, fungal, parasitic, whatever it might be, they're weakening the immune system. And they may sometimes be the actual cause of the cancer because they cause that problem with immune evasion and allow mutations to grow and spread. So when we use these proprietary algorithms that we've developed over several decades, we design custom care that's n of one treatment. And so now the chemo immunoprecision, we can go right to the tumor if we need to direct to tumor if there's resistance. We can also go systemically to the body with micro dosing and targeting because we're removing the guesswork, we're getting the data to guide. Now, it's not that every single patient we treat is automatically cured, but the response rates are significantly higher in our clinical experience as we published in 2024, and getting better and better and better length of life and quality of life. And yes, we do see some fantastic remissions along the way that you wouldn't see without this technology. Restoring and expanding things like natural killer cells and dendritic cells, you know, outside the body and returning. We can actually target the tumors using damps and antigens and tools that allow us to type the immune system specifically for the patient. Combining these targeted treatments, addressing multiple mutations, simultaneously, looking at the metabolic and immune support, but targeted for each patient, makes all the difference in the world. So why this changes everything? Because, Well, n of 1, precision oncology, there's no guessing. We don't just throw a drug or try this regimen, and if it fails, try this other regimen, we guide it. And we use real time adaptive monitoring to make sure the patient's responding. We build the care, guide the care, drive the care step by step with detailed data. It's the difference between firing a missile in the dark and landing a rocket on a dime. Our data proves it. Late stage, particularly complex cancers need this. And the sooner you incorporate precision oncology in our clinical experience, it makes a big difference. We saw that in what we published, but we see that every day clinically. So the future of medicine, I believe is not the double blind placebo clinical trial model. Because with today's AI deep learning all the data we have, this is just takes forever and people suffer through an archaic model. The value of, of population level research is just I don't think there anymore for oncology specifically because we know so much about tumors now. We know the hallmarks of cancer, we can test them, we can understand them. Studies like I predict and wither show how important it is for precision. The more we move to n of 1, the faster we're going to see people see healing responses, longer term care, because we're actually using the modern technology that's available today and letting the data guide. The more unique the targets, the more unique the therapies need to be. And that's what we find. Two people, same type, same stage of cancer, totally needing different therapy. We build it on the pat. And this is the future of oncology. If you or a loved one you know is facing cancer and you don't want to settle for the averages, you don't want a one size fits all, and you don't want to be driving blind anymore. Don't settle for that. Choose precision oncology. Look for it, ask for it. You know, there's even questions you can ask your oncologist, how is this chemotherapy specifically for my cancer? Can you show me its mechanism of action? Can you tell me what the genetic targets are? Can you tell me what the transcriptomic targets are? Can you tell me what the immune system targeting is? Immune profiling. I really challenge you to ask your oncologist this. And over 99% of them will look at you and say, we have no idea. We basically are using a protocol because there's. This has not been typed on you. This is an average clinical trial. This is what we have seen in large cohorts of patients. Because they haven't done the testing, they don't have the molecular profiles in their hands to know what they need to do. And in the end, that is the most important piece. So I encourage you to ask those questions. Challenge your doctors. It's good for them to know, too, that they're kind of flying blind and using protocol driven care. But as you get into later and more complex cancers, these are questions you should be asking. Not being driven into palliative care, sent home to die, or hospice, you should be asking these questions. These are important questions.